Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.

Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, Shacham-Shmueli E, Cosman R, Falcon A, Gort E, Guren T, Massarelli E, Miller WH Jr, Paz-Ares L, Prenen H, Amatu A, Cremolini C, Kim TW, Moreno V, Ou SI, Passardi A, Sacher A, Santoro A, Stec R, Ulahannan S, Arbour K, Lorusso P, Luo J, Patel MR, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL, GO42144 Investigator and Study Group, Han SW

Open source

DOI: 10.1038/s41591-023-02696-8
Published: 2024 Jan
Container: Nature medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-023-02696-8,
  title = {Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.},
  author = {Desai J and Alonso G and Kim SH and Cervantes A and Karasic T and Medina L and Shacham-Shmueli E and Cosman R and Falcon A and Gort E and Guren T and Massarelli E and Miller WH Jr and Paz-Ares L and Prenen H and Amatu A and Cremolini C and Kim TW and Moreno V and Ou SI and Passardi A and Sacher A and Santoro A and Stec R and Ulahannan S and Arbour K and Lorusso P and Luo J and Patel MR and Choi Y and Shi Z and Mandlekar S and Lin MT and Royer-Joo S and Chang J and Jun T and Dharia NV and Schutzman JL and GO42144 Investigator and Study Group and Han SW},
  year = {2024},
  journal = {Nature medicine},
  doi = {10.1038/s41591-023-02696-8},
  url = {https://doi.org/10.1038/s41591-023-02696-8}
}

RIS

TY  - JOUR
TI  - Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
AU  - Desai J
AU  - Alonso G
AU  - Kim SH
AU  - Cervantes A
AU  - Karasic T
AU  - Medina L
AU  - Shacham-Shmueli E
AU  - Cosman R
AU  - Falcon A
AU  - Gort E
AU  - Guren T
AU  - Massarelli E
AU  - Miller WH Jr
AU  - Paz-Ares L
AU  - Prenen H
AU  - Amatu A
AU  - Cremolini C
AU  - Kim TW
AU  - Moreno V
AU  - Ou SI
AU  - Passardi A
AU  - Sacher A
AU  - Santoro A
AU  - Stec R
AU  - Ulahannan S
AU  - Arbour K
AU  - Lorusso P
AU  - Luo J
AU  - Patel MR
AU  - Choi Y
AU  - Shi Z
AU  - Mandlekar S
AU  - Lin MT
AU  - Royer-Joo S
AU  - Chang J
AU  - Jun T
AU  - Dharia NV
AU  - Schutzman JL
AU  - GO42144 Investigator and Study Group
AU  - Han SW
PY  - 2024
JO  - Nature medicine
DO  - 10.1038/s41591-023-02696-8
UR  - https://doi.org/10.1038/s41591-023-02696-8
ER  -

APA

J, D., G, A., SH, K., A, C., T, K., L, M., E, S., R, C., A, F., E, G., T, G., E, M., Jr, M. W., L, P., H, P., A, A., C, C., TW, K., V, M., SI, O., A, P., A, S., A, S., R, S., S, U., K, A., P, L., J, L., MR, P., Y, C., Z, S., S, M., MT, L., S, R., J, C., T, J., NV, D., JL, S., Group, G. I. A. S., & SW, H. (2024). Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.. Nature medicine. https://doi.org/10.1038/s41591-023-02696-8

Source records

pubmed · retrieved 2026-09-26T07:11:16.135Z